Nazal Polipozis Tanı ve Tedavisinde Neredeyiz?

Nazal ve paranasal mukozanın kronik inflamatuar hastalığı olan nazal polipozis, çoğunlukla ön etmoid bölgeden ödemlimukozanın sarkması ve gri renkli polipoid kitleler oluşturması ile karakterize bir hastalıktır. Nazal poliplerin toplumdagörülme oranı %1-4 dür. Hastalarda burun tıkanıklığı, rinore, geniz akıntısı, koku kaybı ve daha az sıklıkta yüz ağrısışikayetlerine yol açabilir. Nazal polip tedavisi bu belirtilerin ortadan kaldırılmasına yönelik medikal ve cerrahi tadavileriiçerir fakat genel kabul görmüş bir tedavi protokolü yoktur. Altta yatan nedene yönelik olarak birçok hipotez ortayaatılsa da etyolojisi halen tam olarak bilinmemektedir. Bu makalede nazal polipozis tanı ve tedavisindeki güncelgelişmeler literatür gözden geçirilerek sunulmuştur.

Where We are in The Diagnosis and Treatment of Nasal Polyposıs?

Nasal polyposis is a chronic inflammatory disease of the nasal and paranasal sinuses mucosa, characterized by prolapse of edematous mucosa as grey polypoid masses, most commonly from the anterior ethmoid region. Nasal polyps are common, affecting up to 1-4 percent of the population. They present with nasal obstruction, rhinorrhoea, post nasal drip, loss of sense of smell, and less commonly facial pain. The management of nasal polyps, aimed at improving these symptoms, includes both surgical and medical treatments, but there is no universally accepted management protocol. Several hypotheses have been put forward regarding the underlying mechanisms but the aetiology is still unknown. In this article, we present the recent advances in the diagnosis and treatment of nasal polyposis by reviewing new guidelines and meta-analysis studies.

PDF

___

1. Larsen K, Tos M. The estimated incidence of symptomatic nasal polyps. Acta Otolaryngol. 2002;122:179–82.
2. Tan BK, Chandra RK, Pollak J, Kato A, Conley DB, Peters AT et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131:1350–60.
3. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp.Allergy. 2015;45:328-46.
4. Kim YS, Kim NH, Seong SY, Kim KR, Lee GB, Kim KS. Prevalence and risk factors of chronic rhinosinusitis in Korea. Am J Rhinol Allergy. 2011;25:117–21.
5. Johansson L, Akerlund A, Holmberg K, Melen I, Bende M. Prevalence of nasal polyps in adults: the Skovde population-based study. Ann Otol Rhinol Laryngol. 2003;112:625–9.
6. Tos M. The pathogenic theories on the formation of nasal polyps. Am J Rhinol. 1990;4:51-6.
7. İsmi O, Özcan C, Polat G, Kul S, Görür K, Pütürgeli T. TNF-α and IL-1 β Cytokine Gene Polymorphism in Patients with Nasal Polyposis. Turk Arch Otorhinolaryngol. 2017;55:51-56.
8. Dar SA, Rai G, Ansari MA, Akhter N, Gupta N, Sharma S, Haque S, Ramachandran VG, Wahid M, Rudramurthy SM, Chakrabarti A, Das S. FcɛR1α gene polymorphism shows association with high IgE and anti-FcɛR1α in Chronic Rhinosinusitis with Nasal Polyposis. J Cell Biochem. 2018;119:4142-9.
9. Bachert C, Zhang N, Patou J, van Zele T, Gevaert P. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol. 2008;8:34–8.
10. Bernstein JM, Ballow M, Schlievert PM, Rich G, Allen C, Dryja D. A superantigen hypothesis for the patho- genesis of chronic hyperplastic sinusitis with massive nasal polyposis. Am J Rhinol. 2003;17:321–6.
11. Sasama J, Sherris DA, Shin SH, Kep- hart GM, Kern EB, Ponikau JU. New paradigm for the roles of fungi and eosinophils in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2005;13:2–8.
12. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:1–298.
13. Bavbek S, Dursun B, Dursun E, Korkmaz H, Sertkaya Karasoy D. The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors. Am J Rhinol Allergy. 2011;25:411–5.
14. Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy. 2009;23:145–8.
15. Settipane GA. Epidemiology of nasal polyps. In Nasal Polyps: Epidemiology, Pathogenesis and Treatment. Settipane GA, Lund VJ, Bernstein JM, and Tos M (Eds). Providence, RI: OceanSide Pubications. 1997;17-24.
16. Schäper C, Noga O, Koch B, Ewert R, Felix SB, Gläser S et al: Anti- inflammatory properties of montelu- kast, a leukotriene receptor antagonist in patients with asthma and nasal pol- yposis. J Investig Allergol Clin Immunol. 2011;21:51-8.
17. Pauli C, Fintelmann R, Klemens C, Hilgert E, Jund F, Rasp G et al: [Polyposis nasi improvement in quality of life by the influence of leukotrien receptor antagonists]. Laryngorhinootologie. 2007;86:282–6.
18. Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M: Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhino- laryngol Relat Spec. 2005;67:148–153.
19. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA: Aspirin desensitization treatment of aspirinsensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98:751-8.
20. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S et al: Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069-1076.e4.
21. Kennedy DW, Kuhn FA, Hamilos DL et al: Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study. Laryngoscope. 2005;115:1793–9.
22. Chan KO, Genoway KA, Javer AR: Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg. 2008;37:870-4.
23. Weschta M, Rimek D, Formanek M, Polzehl D, Podbielski A, Riechelmann H: Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol. 2004;113:1122–8.
24. Cavaliere C, Begvarfaj E, Frati F, Masieri S. Omalizumab a new prospective: a nasal polyposis. J Biol Regul Homeost Agents. 2018;32:167-9.
25. Duffy SM, Lawley WJ, Kaur D, Yang W, Bradding P. Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. J Allergy Clin Immunol. 2003;112:965-72.
26. Pletcher SD, Goldberg AN. Treatment of recurrent sinonasal polyposis with steroid infused carboxymethylcellulose foam. Am J Rhinol Allergy. 2010;24:451–3.
27. Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2007;114:811- 3.
28. Lund VJ, Mackay IS. Outcome assessment of endoscopic surgery. J R Soc Med. 1994;87:70-2.
29. Moriyama H. Postoperative care and long term results. In: Okuda M, editor. Proceedings of the 1991 International Congress of Rhinology. Rhinology. 1992;14:156-9.